Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity. - Wikidata - awgldk - TriplyDB

Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity.

Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity.

http://www.wikidata.org/entity/Q35140978

about

Indications and Results of HLA-Identical Sibling Hematopoietic Cell Transplantation for Sickle Cell Disease 2015 Clinical trials update in sickle cell anemia Advances in sickle cell therapies in the hydroxyurea era Risk Factors of Pulmonary Hypertension in Brazilian Patients with Sickle Cell Anemia Genetic determinants of haemolysis in sickle cell anaemia.Group 5 Pulmonary Hypertension: The Orphan's Orphan Disease.The global burden of pulmonary hypertension in sickle cell disease: a systematic review and meta-analysis.Pulmonary complications of sickle cell disease.Hydroxyurea and a cGMP-amplifying agent have immediate benefits on acute vaso-occlusive events in sickle cell disease mice Stroke in patients with sickle cell disease.Treating sickle cell disease by targeting HbS polymerization Cellular, pharmacological, and biophysical evaluation of explanted lungs from a patient with sickle cell disease and severe pulmonary arterial hypertension Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Challenges in managing pulmonary hypertension in the developing countries.A genome-wide association study of total bilirubin and cholelithiasis risk in sickle cell anemia.Reduction of the six-minute walk distance in children with sickle cell disease is correlated with silent infarct: results from a cross-sectional evaluation in a single center in Belgium Pharmacologic treatments for pulmonary hypertension: exploring pharmacogenomics Elevated pulse pressure is associated with hemolysis, proteinuria and chronic kidney disease in sickle cell disease.A GCH1 haplotype confers sex-specific susceptibility to pain crises and altered endothelial function in adults with sickle cell anemia.The genetics of hemoglobin A2 regulation in sickle cell anemia Severe painful vaso-occlusive crises and mortality in a contemporary adult sickle cell anemia cohort study.Vasculopathy and pulmonary hypertension in sickle cell disease.The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases Echocardiographic markers of elevated pulmonary pressure and left ventricular diastolic dysfunction are associated with exercise intolerance in adults and adolescents with homozygous sickle cell anemia in the United States and United Kingdom.Risk factors and mortality associated with an elevated tricuspid regurgitant jet velocity measured by Doppler-echocardiography in thalassemia: a Thalassemia Clinical Research Network report Pulmonary Haemodynamics in Sickle Cell Disease Are Driven Predominantly by a High-Output State Rather Than Elevated Pulmonary Vascular Resistance: A Prospective 3-Dimensional Echocardiography/Doppler Study.Nitric Oxide-cGMP Signaling Stimulates Erythropoiesis through Multiple Lineage-Specific Transcription Factors: Clinical Implications and a Novel Target for Erythropoiesis.Sickling cells, cyclic nucleotides, and protein kinases: the pathophysiology of urogenital disorders in sickle cell anemia.Genetic polymorphism of APOB is associated with diabetes mellitus in sickle cell disease Pathophysiology and treatment of pulmonary hypertension in sickle cell disease Post splenectomy related pulmonary hypertension.Increased Red Blood Cell Stiffness Increases Pulmonary Vascular Resistance and Pulmonary Arterial Pressure The relationship between the severity of hemolysis, clinical manifestations and risk of death in 415 patients with sickle cell anemia in the US and Europe Longitudinal study of echocardiography-derived tricuspid regurgitant jet velocity in sickle cell disease Sildenafil therapy in thalassemia patients with Doppler-defined risk of pulmonary hypertension A randomized, placebo-controlled trial of arginine therapy for the treatment of children with sickle cell disease hospitalized with vaso-occlusive pain episodes Review: Hemodynamic Characteristics and Outcomes of Sickle Cell Disease Associated Pulmonary Hypertension.Cardiovascular abnormalities in sickle cell disease.Pulmonary hypertension associated with chronic hemolytic anemia and other blood disorders.An official American Thoracic Society clinical practice guideline: diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease.Prediction of fetal hemoglobin in sickle cell anemia using an ensemble of genetic risk prediction models

P2860

Q26779359-9F82744D-5902-4320-8CD6-74450C81D817 Q28086979-0823A0F8-DCA1-4274-92BC-15FFCC02B15F Q28088552-2BF44571-4096-4CA9-AB30-834C89E9452A Q28547742-8ED72A82-FABA-4E07-B451-B1EA0F951707 Q29417116-B64C15D8-EA6C-4051-8FAA-C3753645194A Q30248872-76C5FF69-0D37-4A5B-B8D8-B76FED2B88A3 Q30250302-331624D7-465B-41C3-BCCA-0545D4B147CC Q30515769-5C9F6CF2-3BCB-4341-8380-1859EE23EE24 Q30525565-551E13FE-AB6F-41E6-BCBA-38549F579023 Q30650303-A84C27E2-EB7B-4BAD-A86B-C33B2D5C4D17 Q33707352-472FE080-249E-4426-8D2C-395981B70C41 Q33806253-3BDDC24B-DCA7-4269-9C0F-BEADE4759BE9 Q33965891-276E6595-BC91-406E-9991-14F9BE13FE5C Q34256214-FDE6E184-FFFA-46AA-BE5F-9034B4893B4D Q34282148-C0D212C9-5A56-40A4-9BA4-7E7857744EA8 Q34344390-1F0289C7-C5FA-4B07-99BA-718003E4EF52 Q34639791-15D8CD3B-CD8F-4DE7-80F0-1612100673B7 Q34796372-0118C7C9-1754-49B3-90F9-8EC65664CE03 Q34981612-929F5D77-50D2-4814-8EC5-F9B750161B28 Q35041547-95683C96-961F-454B-80BA-E0E2CDA4C43B Q35086394-9CCF6C01-7FA8-47DB-B607-3F154FF5155F Q35156618-F0A711B7-E0D4-4C92-AA07-24673A4A25F8 Q35243386-16D1D149-5B04-41D2-AFAE-C29954293231 Q35346284-531ACC7B-EBDA-4AE0-9D2F-994C4BAC767B Q35744966-7F42E773-8B48-4B58-86FA-3F2A62F38EE6 Q35883886-9E8095F3-B84B-480D-ABF8-7512C7528158 Q36056143-DF6F060C-3C99-4D52-9446-C879DE846D39 Q36165340-814A9A93-76D3-4C0A-93C6-071E46E40343 Q36596861-5BF68565-E922-4092-AFFE-B3910DEEA78E Q36653460-36097BE3-B62A-49A3-BA0A-750C24734C75 Q36833071-5C8E8AC6-EA28-48C2-B39E-17A754082B8F Q36862364-3A7A763C-EBBC-47FB-AE0A-D156B4DDDE9E Q37138218-CE7B3CA2-3400-4667-85AA-9A3E5D6EDE2E Q37144856-4E90DB36-7436-470C-BF4B-E7B1F5BE61C4 Q37144863-02953141-7EEB-4EF3-ACD6-4352FB6D9EB8 Q37354098-D3B23EAC-0E23-4EBE-BDA3-20FA1B3C5171 Q37435068-A21BEB21-05D6-4446-A046-3B949ACBA318 Q37565002-1729817F-B5F7-4605-8F44-596054B4DDB5 Q37698249-1E58E559-C2DF-4C99-8E2C-E1657C49D09A Q37714937-888DB535-BE98-4224-9321-8EB3B3775BD0

P2860

Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity.

http://www.wikidata.org/entity/Q35140978

description

2011 nî lūn-bûn

@nan

2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Hospitalization for pain in pa ...... TRV and low exercise capacity.

@ast

Hospitalization for pain in pa ...... TRV and low exercise capacity.

@en

type

label

Hospitalization for pain in pa ...... TRV and low exercise capacity.

@ast

Hospitalization for pain in pa ...... TRV and low exercise capacity.

@en

prefLabel

Hospitalization for pain in pa ...... TRV and low exercise capacity.

@ast

Hospitalization for pain in pa ...... TRV and low exercise capacity.

@en

P1433

Q35140978-C0E80972-DA63-428D-A60B-61B9046284AB

P1476

Q35140978-74F4A841-37C5-4FA9-B15F-9CD550700210

P2093

Q35140978-0D169A9E-6874-48F0-95AC-C78F2B72E382

Q35140978-11B501B8-72AD-489A-AE52-657E19009364

Q35140978-11DBFC81-7DD5-4DFA-B6C7-2B0E80E3C3E2

Q35140978-253ED639-DADE-44FD-8F26-3EC44352416E

Q35140978-38E9E9B8-F1E3-42EE-ABA4-71459DFF9713

Q35140978-561E9CAE-6D35-4BDD-9FBB-387FCC3C06E6

Q35140978-5CF9BBDD-2F88-4B1E-B4A9-64D54B9FA208

Q35140978-601C8ECE-F312-43F1-BD9C-D3DAFEE4C97C

Q35140978-75C356A0-851E-4C18-B6C4-FB3754DA1F15

Q35140978-78314E24-2F45-4363-9E90-F2126F324758

P2860

Q35140978-13509E4A-078C-4389-9C9A-722438DAF664

Q35140978-15AADE2D-5085-4B39-80C8-15EAC7A96068

Q35140978-218DC9B5-A630-4983-AE47-25B9F3839D6F

Q35140978-29513095-E6A8-4D29-84DE-9A900362E618

Q35140978-2A1B2FED-36F5-4840-A15D-38E70C6A0EB0

Q35140978-2B0582E3-0671-444F-91F1-5C450E85FD96

Q35140978-3D25ACEA-3A0C-4391-ADCA-344F3553271A

Q35140978-3F2DCDA8-BC59-43A2-8C9E-3DD936D1C04F

Q35140978-4446E141-903F-4EEA-A458-C11578D70B66

Q35140978-5A06E943-C443-4C4A-B970-EF4CC43B01BD

P304

Q35140978-04FCA60F-BA96-417A-BE4B-AE09A605BF62

P31

Q35140978-61AB88DC-0F25-46CA-84D6-293E63D271D6

P356

Q35140978-E1ABED82-E830-4A54-B48A-CEFF393EBBF1

P407

Q35140978-F964309A-AA9E-4307-9FC9-E6E62D7FDB48

P433

Q35140978-685124A1-A778-4F9A-A733-A3945D0EAECB

P478

Q35140978-641C837C-63B5-48FA-8B74-4F36CEBF313C

P50

Q35140978-30583AB0-4360-43FC-8D10-806C2AEA70F2

Q35140978-BB332AA2-DC4B-4986-99DC-379D235142C3

Q35140978-C60C17D6-FD7B-4A46-B9B6-C78546EFFEE0

Q35140978-C736F15A-9E18-4C62-932F-E0ACAB270D13

P577

Q35140978-2F19D9A8-1DA2-4822-AD00-B372BD919C35

P5875

Q35140978-B3B168A1-1084-4D61-A0F5-A9B94C299A0E

P698

Q35140978-B92DF837-792A-4E08-A665-8653C5B316BF

P921

Q35140978-7AF8A13C-FFFD-401B-81F6-2CF54339E00E

Q35140978-ADA63D39-4E28-44EE-AC9D-C80D811B5CA9

Q35140978-D8B3F32A-8C80-4E1B-9CDF-4836FE73E6C2

P932

Q35140978-E6391A4A-FFFD-46DF-874B-192502EFE32A

P356

BLOOD-2010-09-306167

P1433

P1476

Hospitalization for pain in pa ...... TRV and low exercise capacity.

@en

P2093

Claudia R Morris

http://www.w3.org/2001/XMLSchema#string

David B Badesch

http://www.w3.org/2001/XMLSchema#string

J Simon R Gibbs

http://www.w3.org/2001/XMLSchema#string

Jane A Little

http://www.w3.org/2001/XMLSchema#string

Jonathan C Goldsmith

http://www.w3.org/2001/XMLSchema#string

Kathryn L Hassell

http://www.w3.org/2001/XMLSchema#string

Lakshmanan Krishnamurti

http://www.w3.org/2001/XMLSchema#string

Myron A Waclawiw

http://www.w3.org/2001/XMLSchema#string

Nancy A Yovetich

http://www.w3.org/2001/XMLSchema#string

Onyinye Onyekwere

http://www.w3.org/2001/XMLSchema#string

P2860

GTP cyclohydrolase and tetrahydrobiopterin regulate pain sensitivity and persistence

Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial

Updated clinical classification of pulmonary hypertension.

Suppressed injury-induced rise in spinal prostaglandin E2 production and reduced early thermal hyperalgesia in iNOS-deficient mice.

Hemolysis-associated endothelial dysfunction mediated by accelerated NO inactivation by decompartmentalized oxyhemoglobin.

Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease.

Sildenafil inhibits altitude-induced hypoxemia and pulmonary hypertension.

The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease.

Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease

Sildenafil therapy in patients with sickle cell disease and pulmonary hypertension.

P304

855-864

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2010-09-306167

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

118

http://www.w3.org/2001/XMLSchema#string

P50

Gregory J. Kato

Dean E Schraufnagel

Erika Berman-Rosenzweig

P577

2011-04-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51084068

http://www.w3.org/2001/XMLSchema#string

P698

21527519

http://www.w3.org/2001/XMLSchema#string

P921

sickle-cell disease

hospitalization

P932

3148167

http://www.w3.org/2001/XMLSchema#string